Skip to main content

Table 3 Medication treatment at enrollment

From: Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan

Anti-platelet, n (%)

1540 (93)

Anti-coagulant, n (%)

263 (15.88)

ACE-inhibitor, n (%)

356 (21.50)

ARB, n (%)

686 (41.43)

ACE inhibitor/ARB, n (%)

1036 (62.56)

Beta-blockers, n (%)

1074 (64.86)

Calcium-blocker, n (%)

616 (37.20)

Calcium-blocker (DHP), n (%)

543 (32.79)

Diuretics, n (%)

220 (13.29)

Oral nitrates, n (%)

753 (45.47)

Statin, n (%)

1220 (73.67)

PPI, n (%)

87 (5.25)

  1. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, DHP dihydropyridine, PPI proton pump inhibitor